https://rijournals.com/scientific-and-experimental-sciences/

RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(1):41-45, 2025

©RIJSES Publications

ONLINE ISSN: 1115-618X

PRINT ISSN: 1597-2917

https://doi.org/10.59298/RIJSES/2025/514145

The Role of Antimicrobial Medicinal Plants in Combating Drug-Resistant Diarrhea

Mutebi Mark

Department of Pharmacology Kampala International University Uganda
Email: mark.mutebi@studwc.kiu.ac.ug

ABSTRACT

Diarrheal diseases continue to be a major global health concern, particularly in developing regions, where they are a leading cause of morbidity and mortality in children under five. The overuse and misuse of antibiotics in treating diarrheal infections have led to the emergence of multi-drug-resistant (MDR) enteric pathogens, including *Escherichia coli*, *Shigella spp.*, *Salmonella spp.*, and *Vibrio cholerae*. As conventional antibiotics become less effective, there is an urgent need for alternative treatments. Medicinal plants, long used in traditional medicine, have shown promising antimicrobial properties against drug-resistant diarrheal pathogens. This paper investigates the efficacy of antimicrobial medicinal plants such as *Warburgia salutaris*, *Hoslundia opposita*, *Allium sativum*, and *Moringa stenopetala* in treating MDR diarrhea. The study reviews case studies, mechanisms of action, and potential integration into modern healthcare. While these plants offer a viable alternative to conventional antibiotics, challenges such as standardization, regulatory approval, and large-scale clinical validation remain. Future research should focus on in-depth pharmacological studies and policy development to facilitate the incorporation of medicinal plants into mainstream medicine.

Keywords: Antimicrobial medicinal plants, Drug-resistant diarrhea, Multi-drug resistance (MDR), Herbal medicine, Traditional medicine, Enteric infections.

INTRODUCTION

Diarrheal diseases are the second leading cause of death worldwide, taking the lives of around 525,000 children under the age of 5 every year. Inappropriate antimicrobials are often used to treat acute diarrhea, frequently compounded by the prescription of unneeded remedies. Drug resistance in enteric bacteria is a major concern. Furthermore, treating children with a minimal reaction to antibiotics can be dangerous. Among the drugs used most commonly for the treatment of diarrhea are antibiotics. Though beneficial in rapidly controlling the condition, using antibiotics excessively increases drug-resistant strain growth. Instead of addressing the source of a stressful state, an antibiotic can be an incorrect solution. Various microorganisms have developed antibiotic resistance [1, 2]. Most enteric bacteria form colonies resistant to existing antimicrobials. Shigella is a gastrointestinal bacterium resistant to more than 80% of antibiotics. It is increasingly prevalent in bacteria such as Salmonella. Africa, Latin America, and Asia now report alarming resistance patterns. The alarming trend of enteric bacteria developing resistance to existing antimicrobials compels us to explore the efficacy of antimicrobial medicinal plants as alternatives. Medicinal plants have long been seen as the backbone of conventional medicine because they have a lengthy history of being used in traditional medicine. The paper aims to address two main causes of diarrhea and drug resistance [3, 4].

Understanding Drug-Resistant Diarrhea

Diarrheal disease remains a major public health problem worldwide. Managing diarrhea caused by various means is the purpose of doctors, nurses, and pathologists. Any diarrhea becomes difficult to manage once it becomes resistant to drugs. Before attempting to treat any patient, it is important to

understand the rarity and prevalence of the problem, along with the various groups in which it is seen. The resistance of bacteria to conventional medications ultimately leads to their ability to suppress the same pathogenic bacteria, causing the illness after learning to withstand the majority of the drugs, making management difficult. When a bacterium is resistant to one or more drugs, it consequently is not killed when exposed to antibiotics meant to treat it. Multi-drug and extensive-drug resistance in E. coli is a common trait. This includes resistance to penicillins, third-generation cephalosporins, and other antibacterial agents. Multi-drug-resistant E. coli and Shigella species are caused not only by multiple resistance to the commonly available drugs but also due to their resistance to crucial drugs, which include quinolones, lincosamides, and macrolides, to which many patients are allergic. The percentage resistance shown by fifth-generation drugs like carbapenems in clinical isolates of E. coli varies from 18% to 100% according to geography. Antibiotic-resistant enteric infections: One of the major concerns of antibiotic safety in the case of enteric diseases includes antibiotic-resistant enteric infections. Enteric infections, also known as infections that spread from food or water, are a common and serious health concern for large populations. These infections are responsible for diseases like gastroenteritis, causing irritation and inflammation of the stomach and intestines due to exposure to this type of infection. Antibiotics are increasingly used not only to treat diarrhea in these conditions but also as prophylactics to contain the rising severity of the increasing spread of drug-resistant strains and concomitant mortality. Antibiotic resistance is increasingly detected even in therapeutic diarrhea due to usual bacterial causes. Surveillance from multiple countries highlights the prevalence of diarrheal-causing bacteria such as Escherichia coli, Salmonella spp., Shigella spp., and Vibrio cholerae, which are multi-drug resistant. Altered gene transfer mechanisms, as well as restrictions on any antibiotics' usage, are the various mechanisms being utilized to combat this resistance issue. Ecosystems, the environment, and humans are responsible for generating and maintaining antibiotic resistance. Genomic studies reveal that joint studies in the strain of Vibrio cholerae reveal antibiotic-resistant properties being transferred horizontally between pathogens and other virulent genes [5, 6, 7].

Causes and Implications

The dramatic rise in antimicrobial resistance to the most commonly recommended diarrheal disease treatments is the result of both biological and environmental factors. Biological factors include the mutation-based ecology of resistance, a particular concern for bacteria given their unparalleled ability to rapidly acquire and share resistance traits. Environmental factors exacerbate the rise of drug resistance. One major underpinning of environmental resistance is the use and particularly the misuse of antimicrobials. Mass antibiotic usage in animal agriculture, cases of overprescribing by healthcare providers, or the dispensing of these drugs without requisite prescription or oversight are primary contributors to drug-resistant disease [8, 9]. Diarrheal disease is highly contagious and can easily spread among households, public areas, and entire communities. An estimated 2 billion cases occur in children every year, causing up to 15% of all deaths in kids under age 5 worldwide. Developing countries often lack the resources to provide and enforce clean, safe conditions for water, sanitation, and hygiene, which are the primary ways to prevent diarrheal disease from occurring in children. Compounding the issue is the increasingly apparent capacity for bacteria to spread from younger to older individuals, thereby sharing drug-resistant pathogens with greater populations. These are all real factors in creating ideal conditions for the rise and transmission of drug resistance. Understanding the factors that underpin the emergence of drug resistance can lead the way to strategies to address underlying causes and prevent the disease from occurring or the condition from worsening [10, 11].

Antimicrobial Properties of Medicinal Plants

There exist various plants that have demonstrated antimicrobial properties, indicating their possible use as alternatives to classical antibiotics. For example, Euphorbia abyssinica contains bioactive compounds that are active against methicillin-resistant Staphylococcus aureus. Vohlivialiantha contains peptides that are effective against multidrug-resistant Mycobacterium avium. Allium sativum contains allicin, which has antiplasmid activity against E. coli. For the active compounds found in the investigated plants countering diarrhea-causing and multidrug-resistant pathogens, the following mechanisms are described: 1) The bioactive compounds inhibit the expression of efflux pumps, effectively increasing the sensitivity of the pathogen to common pharmaceuticals, even multidrug-resistant ones. 2) The bioactive compounds may also attack the cell walls of the pathogens, causing cell lysis. 3) Plants containing bioactive compounds may maintain normal flora in the gut, diminishing dehydration and maintaining soft stool in affected persons. For centuries, gastrointestinal infections have been treated with traditional medicine. Research and development of plants' bioactive compounds that counter diarrhea with a focus on inhibiting

drug expulsion and eradicating associated pathogens have already begun, proving the effectiveness once again. It is then hypothesized that plant species worldwide, in local areas of cultivation, could be developed as low-cost, synergistic alternatives or complements to classical antimicrobial diarrhea therapy. It may very well be that in a rural community heavily affected by drug resistance, resistance to the active compounds in medicinal plants has not developed, making it an invaluable backup solution. Botanical drugs have successfully been integrated into modern pharmaceuticals [12, 13, 14].

Case Studies and Efficacy

Case Study 1. Warburgia salutaris, Hoslundia opposita, and Strychnos madagascariensis: All of the plants in this study are obtained from traditional practitioners practicing within the hospital's catchment area. The doses of WM and HM are those used by the traditional healer, employed for adults and patients above 5 years and children less than 5 years. Overall, 22/30 and 9/12 patients in the two arms given WM and HM respectively recovered. There were no significant differences between the outcomes in the WM and HM-treated groups, although the initial recovery in 4 days was noted in HM, which was shorter than in the WM arm where it ranged from 6 to 14 days. Preparation methods, dosage, and application may vary, which might affect product efficacy. For legal clarification by the government, extensive studies are still required to ascertain the effectiveness of MP in agreement with the scientific requirement, i.e., the development of national guidelines for MPM with a focus on quality assurance and safety monitoring for further public use. There is enough evidence of HM being used alone in the treatment of drug-resistant groups, confirming its efficiency above 50% in patients who are resistant to drugs [15, 16, 17]. Case Study 2. Decoction of Warburgia salutaris, Hoslundia opposita, Amaranthus graecizans, Azadirachta indica, and Moringa stenopetala were empirically employed in the outpatient clinic of controls between 2007 and 2009. The treatment regimen and outcome reports can only be compiled based on case files. The retrospective cohort study, which is treated strictly according to national regulations in its respective version, is accessible for adults as well as children over 10 years of age; children aged 6 to 10; and non-pregnant patients. A total of 10 patients were respectively given full-scale DRM, IRM, and HOM. Full-scale DRM and IRM, which were chosen to complement DRG therapies, were assigned to seven different subjects with different dose indications. Relevant for study purposes, the few cases of strict MPM exposure, IRM, and HOM, on their own or in increased doses, showed noteworthy recovery percentages. Management of drug-resistant E. coli in 16 cases disclosed varied efficacy of MP alone. In detail, MPs as DM, Functioning-Resistant Antidiarrheal, or DRG complemented with full DRM dosage, and good FA, proved effective in about 75%, 70%, and 63% of cases, respectively [18, 19, 20].

Challenges and Future Directions

Integration of antimicrobial medicinal plants into current healthcare systems poses several challenges in terms of safety and efficacy. Modern medicine requires drug standardization, tight quality control, and regulatory frameworks. It is important to distinguish ethnopharmacological efficacy from geographical and temporal variations. For instance, environmental growing conditions may affect the efficacy of plants. While traditional knowledge of antiamoebic plant use is based on expert judgment, modern medicine demands quantitative parameters. There are also substantial differences between traditional and modern plant use. For instance, seven of the ten antiamoebic plants could not be used safely in moderate dosages, say three times a day over ten days. Overall, these results revealed a large gap between traditional plant use and modern requirements for inclusion in standard medicine and healthcare. While advocating further research on novel drugs from plants, the possible applications of plants with moderate antimicrobial potential should not be disregarded. A combination of in vivo studies in the target population and in vitro studies could help to identify the plants with high potential. Several future research options are recommended. Specifically, the use of cross-cultural data is suggested for several therapeutic application areas. With the extinction of both ancient healers and plants, traditional knowledge of medicinal plants is at risk of being lost. Distortion and loss of knowledge may lead to a depletion of the most useful measures to fight drug-resistant diarrhea. Geographical data could be combined with methods for finding relevant bioactivity, target molecules, and other relevant medical information. In addition, publicly funded research is driven by the public health needs of society. To engage the public and bring them to a point where they can discuss openly what constitutes an acceptable public health standard in support of further scientific research, it could be of value to educate the public about the most straightforward uses of medicinal plants across different cultures and societies. The use of medicinal plants in many parts of the world is not a phenomenon of poverty or dereliction but is a simple sound choice. A convincing story about the value of medicinal plants in healthcare resonates well with many people, judging by their behavior when they get sick. Furthermore, efforts should be taken to create an understanding of policy.

Regulators and politicians are the ultimate gatekeepers of safe and effective antimicrobials. Once they realize that herbal medicinal plants do indeed have potential gaps in the market, they could be supportive in the development of methods and standards required to fill that gap. Policies could include: the demand for good-quality medicinal plants in a post-industrial environmental economy; investment in selected unpatented drug discovery research on medicinal plants, including the observation of cultural approaches and their application to selected unmet needs and opportunities in healthcare; the development of standards that reflect the unpatented and often geographical nature of plant preparations; commitment to the use of the results of this knowledge in post-surgical therapeutics and the preservation of its contents in non-privatized form [21, 22, 23, 24, 25].

CONCLUSION

Antimicrobial medicinal plants provide a promising solution to the growing challenge of drug-resistant diarrheal diseases. With their rich history in traditional medicine and demonstrated efficacy against MDR enteric pathogens, these plants can serve as either standalone treatments or adjuncts to existing therapies. However, their full potential can only be realized through further scientific validation, standardization, and regulatory oversight. Bridging the gap between traditional herbal knowledge and modern medicine requires multidisciplinary collaboration among researchers, policymakers, and healthcare practitioners. As antibiotic resistance continues to threaten global health, harnessing the therapeutic potential of medicinal plants presents an innovative and sustainable approach to combating drug-resistant diarrhea.

REFERENCES

1. Behera DK, Mishra S. The burden of diarrhea, etiologies, and risk factors in India from 1990 to 2019: evidence from the global burden of disease study. BMC public health. 2022 Dec;22:1-9.
2. Thystrup C, Majowicz SE, Kitila DB, Desta BN, Fayemi OE, Ayolabi CI, Hugho E, Buys EM, Akanni GB, Machava NE, Monjane C. Etiology-specific incidence and mortality of diarrheal diseases in the African region: a systematic review and meta-analysis. BMC Public Health. 2024 Jul 12;24(1):1864. springer.com
3. Liu HY, Prentice EL, Webber MA. Mechanisms of antimicrobial resistance in biofilms. npj Antimicrobials and Resistance. 2024 Oct 1;2(1):27.
4. Ali Y, Inusa I, Sanghvi G, Mandaliya VB, Bishoyi AK. The current status of phage therapy and its advancement towards establishing standard antimicrobials for combating multi drug-resistant bacterial pathogens. Microbial Pathogenesis. 2023 Aug 1;181:106199. [HTML]
5. Sharif N, Ahmed SN, Khandaker S, Monifa NH, Abusharha A, Vargas DL, Díez ID, Castilla AG, Talukder AA, Parvez AK, Dey SK. Multidrug resistance pattern and molecular epidemiology of pathogens among children with diarrhea in Bangladesh, 2019–2021. Scientific Reports. 2023 Aug 26;13(1):13975. nature.com
6. Mason LC, Greig DR, Cowley LA, Partridge SR, Martinez E, Blackwell GA, Chong CE, De Silva PM, Bengtsson RJ, Draper JL, Ginn AN. The evolution and international spread of extensively drug resistant Shigella sonnei. nature communications. 2023 Apr 8;14(1):1983. nature.com
7. Choudhary A, Midha T, Gulati I, Baranwal S. Isolation, Genomic Characterization of Shigella prophage fPSFA that effectively infects multi-drug resistant Shigella isolates from the Indian Poultry Sector. Microbial Pathogenesis. 2024 Mar 1;188:106538.
8. Gebeyehu DT. Antibiotic resistance development in animal production: a cross-sectional study. Veterinary Medicine: Research and Reports. 2021 May 18:101-8.
9. Pignataro G, Di Prinzio R, Crisi PE, Belà B, Fusaro I, Trevisan C, De Acetis L, Gramenzi A. Comparison of the therapeutic effect of treatment with antibiotics or nutraceuticals on clinical activity and the fecal microbiome of dogs with acute diarrhea. Animals. 2021 May 21;11(6):1484. mdpi.com
10. Osendarp S, Akuoku JK, Black RE, Headey D, Ruel M, Scott N, Shekar M, Walker N, Flory A, Haddad L, Laborde D. The COVID-19 crisis will exacerbate maternal and child undernutrition and child mortality in low-and middle-income countries. Nature food. 2021 Jul;2(7):476-84. nature.com
11. Manetu WM, M'masi S, Recha CW. Diarrhea disease among children under 5 years of age: a global systematic review. Open Journal of Epidemiology. 2021 Jun 28;11(3):207-21.

12. Pancu DF, Scurtu A, Macasoi IG, Marti D, Mioc M, Soica C, Coricovac D, Horhat D, Poenaru M, Dehelean C. Antibiotics: conventional therapy and natural compounds with antibacterial activity—a pharmaco-toxicological screening. Antibiotics. 2021 Apr;10(4):401. mdpi.com
13. Arsene MM, Jorelle AB, Sarra S, Viktorovna PI, Davares AK, Ingrid NK, Steve AA, Andreevna SL, Vyacheslavovna YN, Carime BZ. Short review on the potential alternatives to antibiotics in the era of antibiotic resistance. Journal of Applied Pharmaceutical Science. 2021 Dec 27;12(1):029-40. japsonline.com
14. Álvarez-Martínez FJ, Barrajón-Catalán E, Herranz-López M, Micol V. Antibacterial plant compounds, extracts and essential oils: An updated review on their effects and putative mechanisms of action. Phytomedicine. 2021 Sep 1;90:153626. sciencedirect.com
15. Mba IE, Nweze EI. Focus: antimicrobial resistance: antimicrobial peptides therapy: an emerging alternative for treating drug-resistant bacteria. The Yale journal of biology and medicine. 2022 Dec;95(4):445.
16. Suganya T, Packiavathy IA, Aseervatham GS, Carmona A, Rashmi V, Mariappan S, Devi NR, Ananth DA. Tackling multiple-drug-resistant bacteria with conventional and complex phytochemicals. Frontiers in Cellular and Infection Microbiology. 2022 Jun 30;12:883839. frontiersin.org
17. Shlobin NA, Sander JW. Current principles in the management of drug-resistant epilepsy. CNS drugs. 2022 Jun;36(6):555-68.
18. Parker EN, Cain BN, Hajian B, Ulrich RJ, Geddes EJ, Barkho S, Lee HY, Williams JD, Raynor M, Caridha D, Zaino A. An iterative approach guides discovery of the FabI inhibitor fabimycin, a late-stage antibiotic candidate with in vivo efficacy against drug-resistant Gram-negative infections. ACS Central Science. 2022 Aug 10;8(8):1145-58. acs.org
19. Abdelaziz AA, Kamer AM, Nosair AM, Al-Madboly LA. Exploring the potential efficacy of phage therapy for biocontrol of foodborne pathogenic extensively drug-resistant Escherichia coli in gastrointestinal tract of rat model. Life Sciences. 2023 Feb 15;315:121362.
20. Moon BY, Ali MS, Kwon DH, Heo YE, Hwang YJ, Kim JI, Lee YJ, Yoon SS, Moon DC, Lim SK. Antimicrobial resistance in Escherichia coli isolated from healthy dogs and cats in South Korea, 2020–2022. Antibiotics. 2023 Dec 27;13(1):27.
21. Ashraf MV, Pant S, Khan MH, Shah AA, Siddiqui S, Jeridi M, Alhamdi HW, Ahmad S. Phytochemicals as antimicrobials: prospecting Himalayan medicinal plants as source of alternate medicine to combat antimicrobial resistance. Pharmaceuticals. 2023 Jun 15;16(6):881. mdpi.com
22. Tiwari P, Bajpai M, Sharma A. Antimicrobials from medicinal plants: Key examples, success stories and prospects in tackling antibiotic resistance. Letters in Drug Design & Discovery. 2023 Apr 1;20(4):420-38. [HTML]
23. Abdallah EM, Alhatlani BY, de Paula Menezes R, Martins CH. Back to Nature: Medicinal plants as promising sources for antibacterial drugs in the post-antibiotic era. Plants. 2023 Aug 28;12(17):3077. mdpi.com
24. Nwodo O, Parker J, Ugwu O. Acute toxicity investigation and anti-diarrhoeal effect of the chloroform-methanol extract of the leaves of *Persea americana*. Iran J Pharm Res. 2014;13(2):651.
25. Odo CE, Nwodo FC, Joshua PE, Ugwu PC, Okonkwo CC. Acute toxicity investigation and anti-diarrhoeal effect of the chloroform–methanol extract of the seeds of *Persea americana* in albino rats. J Pharm Res. 2013;6(3):331-5.

CITE AS: Mutebi Mark (2025). The Role of Antimicrobial Medicinal Plants in Combating Drug-Resistant Diarrhea. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(1):41-45. https://doi.org/10.59298/RIJSES/2025/514145